Westlake BioPartners?

We are thrilled to announce that Latigo Biotherapeutics has secured $150 million in Series B funding to advance our mission of developing non-opioid pain therapeutics. This financing, led by funds managed by Blue Owl Capital, will accelerate the clinical development of our Nav1.8 inhibitors and expand our pipeline of innovative treatments. We welcome Senior Managing Director Kevin Raidy from Blue Owl Capital to our board of directors. Thank you to our new investors Deep Track Capital, Access Biotechnology, Qatar Investment Authority, Cormorant Asset Management, Sanofi Ventures, Rock Springs Capital, UPMC Enterprises, and Kern Capital as well as the further commitment of existing investors Westlake BioPartners?, Foresite Capital, 5AM Ventures, and Alexandria Venture Investments. Together, we are poised to address the urgent need for non-opioid pain solutions and improve the lives of those affected by pain. Read the full press release: https://lnkd.in/gHJFupPx #Biopharma #Biotech #Biotechnology #PharmaNews

We’re excited to share that Bristol Myers Squibb has exercised its exclusive license option for our AB-4000 series as part of our multi-program collaboration to develop next-generation T cell therapies for solid tumors. This milestone demonstrates confidence in our programmable cell therapy platform and marks a key step toward advancing innovative solutions for patients battling solid tumor cancers. The AB-4000 series leverages ArsenalBio’s proprietary biological toolkit designed to overcome the challenges of addressing solid tumors, including targeting specificity and a suppressive tumor microenvironment. Thank you to the teams at ArsenalBio and Bristol Myers Squibb for their hard work and collaboration. Together, we’re pushing the boundaries of what’s possible in cancer treatment. Learn more via our latest press release. https://bit.ly/4h3hg2w

We’re excited to welcome Christian Hordo as our new CEO, along with a $30 million infusion from an extension of the Series A led by Westlake BioPartners and the addition of three new board directors, David Allison, Tom Frohlich and Catherine Thut. ? With the Series A expansion, the company now has $180 million of capital to develop next-generation RNA medicines for kidney disease.?? ? Learn more at https://lnkd.in/gVA-2x7y #biotech #RNA #kidneydisease

I’m pleased to share that Novartis has acquired Kate Therapeutics. This is an exciting deal that bolsters our pipeline and brings expertise and capabilities that complement our work to advance novel gene therapies with transformative potential for people with inherited neuromuscular diseases. ? We believe that Kate's innovative technology platforms, combined with our scientific expertise, leadership and ongoing internal efforts in gene therapy and neuroscience, will position us well to address some of the limitations of existing gene therapies and bring new options to patients with these disorders. ? Thank you to the teams at both Novartis and Kate who worked so hard to get this acquisition across the finish line.? https://lnkd.in/enaNj_qg

We are very pleased to announce the appointment of Tim Walbert as the new Chairman of the Board of Directors at Latigo! Tim is a highly respected leader in the biopharmaceutical sector, most recently serving as chairman, president, and CEO of Horizon Therapeutics, which was acquired by Amgen for over $28 billion. He brings a wealth of experience and a stellar track record, having led IDM Pharma to its acquisition by Takeda and orchestrated the global launch of HUMIRA? at Abbott, alongside influential roles at several other top-tier companies. Our CEO, Nima Farzan, expressed his enthusiasm about Tim’s appointment, stating, “Tim’s proven ability to build successful biopharma companies and his dedication to patient-centered innovation align perfectly with our mission to deliver effective and safer alternatives for individuals suffering from acute and chronic pain.” A heartfelt thank you to our previous Chair, Nancy Stagliano, whose invaluable guidance has been instrumental in establishing our company and advancing our mission. To read the full announcement, click here: https://lnkd.in/gHJFupPx #BioPharma #Biotech #BiotechNews

We are excited to announce the appointment of Tim Lugo as our new Chief Financial Officer and the addition of Beth Seidenberg, M.D., and Jim Tananbaum, M.D., to our board of directors. Tim brings over two decades of experience in biotechnology finance and equity research, while Dr. Seidenberg and Dr. Tananbaum are seasoned venture capitalists. Their expertise will be instrumental as we scale and accelerate the development of our non-opioid pain medicines. Welcome to the Latigo Biotherapeutics, Inc. team! Click the link below to read the full press release. ?? https://lnkd.in/gHJFupPx #NonOpioidPainRelief #Leadership #BioPharma

We are excited to announce our $325 million #SeriesC financing.? This new investment will enable ArsenalBio's ongoing development efforts and scale our manufacturing capabilities to develop T-cell medicines.? We thank the new investors along with our existing investors for their support in helping us to achieve our goal to defeat cancer. #celltherapy #patientsfirst https://lnkd.in/dimnsnfm

Today, we announced new Phase 1 data about the safety and tolerability of our therapeutic approach that may provide pain patients with an alternative to opioids. LTG-001 is an oral, selective Nav1.8 inhibitor in development to treat acute and chronic pain at its source. Opioid addiction is a national public health concern – 3.75 million Americans go on to long-term chronic opioid use after low-risk surgery as up to 19% of patients exposed to opioids develop dependency. We are also thrilled to welcome world-renowned analgesic scientist Neil Singla, MD as our chief medical officer. Learn more about these results and our commitment to provide effective, rapid-acting pain relief without the risk of addiction. https://lnkd.in/guXWFrrv #BioPharma #Biotechnology #Pharma #News #PainManagement #NonOpioid